--- title: "Skinvisible (SKVI) stock listing, news and investor profile" url: "https://aibio.space/companies/skinvisible/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "Skinvisible, Inc. (OTC: SKVI), United States. The directory classifies it as Pharmaceuticals: Major." --- SKVI Skinvisible, Inc. OTC · United States # Skinvisible (SKVI) news Distress · 2025-03-31 ## [Skinvisible delays annual report for year ended December 31, 2024](https://aibio.space/news/skinvisible-delays-annual-report-year-ended-december-31-2024/) The company said it could not compile all the information for its financial statements in time. It expects to file within the fifteen-day grace period. ## Latest Skinvisible news We have not published a story on Skinvisible yet. When there is news, it will appear here. ## Skinvisible at a glance - **Ticker**: SKVI - **Listing**: OTC - **Country**: United States - **Cash, Jun 30, 2026**: $3,959 ### Related companies - [Actinium Pharmaceuticals, Inc. (Delaware)](https://aibio.space/companies/actinium-pharmaceuticals-delaware/) AMEX: ATNM - [Vogenx](https://aibio.space/companies/vogenx/) NASDAQ: VOGX - [Evelo Biosciences](https://aibio.space/companies/evelo-biosciences/) OTC: EVLO - [Verrica Pharmaceuticals](https://aibio.space/companies/verrica-pharmaceuticals/) NASDAQ: VRCA - [Enanta Pharmaceuticals](https://aibio.space/companies/enanta-pharmaceuticals/) NASDAQ: ENTA - [MannKind](https://aibio.space/companies/mannkind/) NASDAQ: MNKD - [Cullinan Therapeutics](https://aibio.space/companies/cullinan-therapeutics/) NASDAQ: CGEM - [Actuate Therapeutics](https://aibio.space/companies/actuate-therapeutics/) NASDAQ: ACTU ### Also on OTC - [Inhibitor Therapeutics](https://aibio.space/companies/inhibitor-therapeutics/) INTI - [CytoDyn](https://aibio.space/companies/cytodyn/) CYDY - [EAGLE PHARMACEUTICALS INC](https://aibio.space/companies/eagle-pharmaceuticals/) EGRX - [CV Sciences](https://aibio.space/companies/cv-sciences/) CVSI - [Anebulo Pharmaceuticals](https://aibio.space/companies/anebulo-pharmaceuticals/) ANEB - [Avenue Therapeutics](https://aibio.space/companies/avenue-therapeutics/) ATXI ## What Skinvisible does Skinvisible, Inc. is a pharmaceutical research and development company that has developed and patented Invisicare, a polymer delivery system for topical skin products. The company says it has formulated over forty topical skin products, which it out-licenses globally to established manufacturers and marketers. It targets an estimated $80 billion global skincare and dermatology market and a $30 billion global over-the-counter market. Invisicare is designed to bind active ingredients to the skin for extended periods and to deliver them in a controlled release. Skinvisible generates revenue through licensing for an upfront fee and ongoing royalties, through co-development of early formulations for pharmaceutical clients, and through life cycle management that reformulates off-patent products with new Invisicare patents. Its licensee Quoin Pharmaceuticals, Inc. holds rights to certain patents for QRX003, a topical product being developed for Netherton Syndrome. The agreement calls for a $5 million milestone to Skinvisible upon the first FDA or European Union approval for one licensed product, and a single digit royalty on net sales. | Product or program | What it is | Stage | |---|---|---| | Invisicare | Patented polymer delivery system for topical skin care products | patented | | QRX003 | Topical product licensed to Quoin for Netherton Syndrome | in clinical trials (Quoin) | Summarised from the company's [10-K filed Mar 31, 2026](https://www.sec.gov/Archives/edgar/data/1085277/000166357726000087/skvi10k_123125.htm). ## Skinvisible annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$20,000](https://www.sec.gov/Archives/edgar/data/1085277/000166357726000087/) | [$20,000](https://www.sec.gov/Archives/edgar/data/1085277/000166357726000087/) | | Net income (loss) | [-$1.1 million](https://www.sec.gov/Archives/edgar/data/1085277/000166357726000087/) | [-$565,654](https://www.sec.gov/Archives/edgar/data/1085277/000166357726000087/) | | Cash from operations | [-$38,410](https://www.sec.gov/Archives/edgar/data/1085277/000166357726000087/) | [-$69,834](https://www.sec.gov/Archives/edgar/data/1085277/000166357726000087/) | | Cash and equivalents | [$2,620](https://www.sec.gov/Archives/edgar/data/1085277/000166357726000248/) | [$10,336](https://www.sec.gov/Archives/edgar/data/1085277/000166357726000248/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $3,959. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Skinvisible What is the ticker symbol of Skinvisible? Skinvisible, Inc. trades under the ticker SKVI on OTC. Where is Skinvisible listed? Skinvisible, Inc. is listed on OTC. What is the SEC CIK of Skinvisible? The SEC Central Index Key (CIK) for Skinvisible, Inc. is 1085277. Its filings are on SEC EDGAR. How many shares does Skinvisible have outstanding? 5,403,843 shares as of 2026-08-13, per the cover page of its 10-Q filed 2026-08-13. Which country or territory is Skinvisible listed under? Our directory records Skinvisible, Inc. under United States. What does Skinvisible do? Our directory classifies Skinvisible, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Skinvisible? The ISIN recorded for Skinvisible, Inc. is US8307032032. Does aibio.space cover Skinvisible? aibio.space lists Skinvisible, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Skinvisible incorporated? SEC records list its state or country of incorporation as NV. What does Skinvisible develop? Skinvisible, Inc. is a pharmaceutical research and development company that has developed and patented Invisicare, a polymer delivery system for topical skin products. The company says it has formulated over forty topical skin products, which it out-licenses globally to established manufacturers and marketers. What is Invisicare from Skinvisible? Invisicare: Patented polymer delivery system for topical skin care products Stage: patented. What is QRX003 from Skinvisible? QRX003: Topical product licensed to Quoin for Netherton Syndrome Stage: in clinical trials (Quoin). What was Skinvisible's revenue last year? $20,000 for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Skinvisible profitable? Skinvisible, Inc. reported a net loss of $1.1 million for the fiscal year ended Dec 31, 2025, and used $38,410 of cash in operations, per its annual report to the SEC. How much cash does Skinvisible have? $3,959 in cash at Jun 30, 2026, per its 10-Q. ## Investor discussion: Skinvisible Members talk about Skinvisible (SKVI). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Skinvisible, newest first. Each line links the filing it comes from. 1. 2026-03-31 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1085277/000166357726000087/skvi10k_123125.htm) 2. 2025-04-14 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1085277/000166357725000110/skvi10k123124.htm) 3. 2025-03-31 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1085277/000166357725000088/skvi_nt10k.htm) 4. 2024-11-14 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1085277/000166357724000289/skvi_nt10q3.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open OTC:SKVI on TradingView](https://www.tradingview.com/symbols/OTC-SKVI/). ## SEC filings and registration - **SEC name**: Skinvisible, Inc. - **CIK**: 1085277 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: SKVI (OTC) - **State or country of incorporation**: NV - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 6320 S SANDHILL ROAD, LAS VEGAS, NV, 89120 - **Phone**: 702-433-7154 - **Shares outstanding**: 5,403,843 as of 2026-08-13 (10-Q filed 2026-08-13) - **Former names**: SKINVISIBLE INC ### Recent filings (8-K and 6-K are the company's own announcements) - [10-Q](https://www.sec.gov/Archives/edgar/data/1085277/000166357726000248/skvi10q2_063026.htm) filed 2026-08-13 - [10-Q](https://www.sec.gov/Archives/edgar/data/1085277/000166357726000141/skvi10q1_033126.htm) filed 2026-05-13 - [10-K](https://www.sec.gov/Archives/edgar/data/1085277/000166357726000087/skvi10k_123125.htm) filed 2026-03-31 - [10-Q](https://www.sec.gov/Archives/edgar/data/1085277/000166357725000309/skvi10q3_093025.htm) filed 2025-11-13 - [10-Q](https://www.sec.gov/Archives/edgar/data/1085277/000166357725000261/skvi10q2_06302025.htm) filed 2025-08-13 - [10-Q](https://www.sec.gov/Archives/edgar/data/1085277/000166357725000136/skvi10q1_033125.htm) filed 2025-05-14 - [10-K](https://www.sec.gov/Archives/edgar/data/1085277/000166357725000110/skvi10k123124.htm) filed 2025-04-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1085277/000166357725000033/skvi8k_012325.htm) filed 2025-01-23 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001085277), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Skinvisible, Inc. is a public biotech or pharmaceutical company listed on OTC under the ticker SKVI, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Skinvisible, Inc. - **Ticker**: SKVI - **Listing**: OTC - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US8307032032 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/OTC-SKVI/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/skinvisible/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Skinvisible (SKVI) stock listing, news and investor profile", 2026-10-31, https://aibio.space/companies/skinvisible/